Abstract 3547
Background
With the increased use of ICIs among cancer patients, there is growing interest in understanding the outcome and management of irAEs. This study addressed this knowledge gap by examining the real-world outcomes in patients experiencing irAEs.
Methods
An observational study was conducted using the Premier Healthcare Database, a US national hospital discharge database (Mar 2015-Dec 2017). Twenty-eight distinct types of irAEs per the ASCO practice guidelines were identified. Patients with ICD-9/10 codes for NSCLC, RCC, UC, or MCC and one of 28 irAEs during the study period were included. Index irAE visits were defined as the first visit with a confirmed ICI usage during a 90-day look-back period from the first irAE. Patients were then followed for 90 days post-irAE to determine irAE-related inpatient admissions, all-cause in-hospital mortality, and ICI re-initiation.
Results
15,277 distinct irAEs occurred across 13,030 patients, with 5,732 (38%) of irAE events with an inpatient index visit. Among the 6590 patients having ≥1 irAEs, 44% had 1 irAE of any type, 25% had 2, 14% had 3, and 17% had ≥4 irAEs. Among the 28 types of irAEs, inpatient index visits were most common for myocarditis, transverse myelitis, and toxic epidermal necrolysis (all 100%), and least common for acquired hemophilia (0%), polymyalgia-like syndrome (10%), and adrenal insufficiency (10%). During the follow-up period, patients with inpatient index admissions had higher (p < 0.001) subsequent inpatient admissions and higher mortality, and lower (p < 0.001) ICI re-initiation (Table).Table:
1284P
Index Visit Type | |||
---|---|---|---|
Clinical outcome: 90 days following index irAE | All | Inpatient | Outpatient |
irAE-related inpatient admission | 23% | 26%* | 19%* |
No ICI re-initiation | 47% | 70%** | 28%** |
All-cause inpatient mortality | 12% | 23%*** | 6%*** |
p < 0.001,
**p < 0.001,
***p < 0.001
Conclusions
Approximately half of patients receiving an ICI experienced an irAE that required clinical management in inpatient or outpatient setting. Occurrence of irAEs was associated with treatment discontinuation. Overall, irAE cases with inpatient index visits tended to have poor outcomes and required more follow-up management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EMD Serono, Inc.
Funding
This study was sponsored by EMD Serono, Inc, a business of Merck Healthcare KGaA, Darmstadt, Germany, and is part of an alliance between EMD Serono/Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY, USA.
Disclosure
S. George: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Novartis; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Corvus; Advisory / Consultancy: Genentech; Advisory / Consultancy: Sanofi/Genzyme; Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Inc; Research grant / Funding (institution): Acceleron; Research grant / Funding (institution): Merck ; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Eisai; Advisory / Consultancy: EMD Serono, Inc. Y. Zheng: Full / Part-time employment, current employment (self): EMD Serono, Inc; Full / Part-time employment, previous employment (self) : Janssen; Licensing / Royalties, Full / Part-time employment, spouse and immediate family: Shire (now Takeda); Full / Part-time employment, spouse: Eli Lilly. R. Kim: Full / Part-time employment: Pfizer, Inc.; Shareholder / Stockholder / Stock options: Exelixis. T. Yu: Full / Part-time employment: EMD Serono, Inc. J. Dreyfus: Shareholder / Stockholder / Stock options, Full / Part-time employment: Premier, Inc. J.A. Gayle: Full / Part-time employment: Premier, Inc. C. Wassel: Full / Part-time employment: Premier, Inc. H. Phatak: Full / Part-time employment: EMD Serono, Inc.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract